Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder

Brexpiprazole is an atypical antipsychotic that works as a partial agonist at serotonin 5-hydroxytryptamine(1A) and dopamine D(2) receptors and an antagonist at serotonin 5-hydroxytryptamine(2A). It has US Food and Drug Administration approval for monotherapy treatment of schizophrenia and adjunctiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Diefenderfer, Lauren A., Iuppa, Courtney
Formato: Online Artículo Texto
Lenguaje:English
Publicado: College of Psychiatric & Neurologic Pharmacists 2018
Materias:
Review of Drugs/Pharmacotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007711/
https://www.ncbi.nlm.nih.gov/pubmed/29955525
http://dx.doi.org/10.9740/mhc.2017.09.207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007711/
https://www.ncbi.nlm.nih.gov/pubmed/29955525
http://dx.doi.org/10.9740/mhc.2017.09.207

Ejemplares similares